2상모집 중
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
연구 개요
The purpose of this study to find out whether sacituzumab govitecan in combination with cetuximab is an effective and safe treatment approach for people with recurrent and/or metastatic head and neck squamous cell cancer (HNSCC).
- 스폰서
- 협력: 길리어드
- 적응증
- Squamous Cell Carcinoma of Head and Neck, Sinus Cancer, Nasal Cavity Cancer, Oral Cavity Cancer, Oropharynx Cancer, Hypopharynx Cancer, Larynx Cancer, Oral Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- 중재
- Sacituzumab Govitecan, Cetuximab
- 목표 등록
- 40명
- 시작일
- 2025-07-02
- 완료(예정)
- 2028-01-02
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.